SmartNanoSense (SNSI) plays a central role in VOLABIOS by leading the development, optimization, and in-lab validation of cutting-edge ion mobility spectrometry (IMS) technologies for the detection of volatile organic compounds (VOCs) linked to schizophrenia. Drawing on its expertise in nano-sensor technology, real-time chemical analysis, and portable diagnostic devices, SNSI is responsible for customizing and integrating IMS systems capable of capturing and analyzing VOCs emitted through various bodily fluids—such as breath, skin, blood, and urine—with exceptional sensitivity down to parts per billion (ppb). These systems are designed to function under a wide range of clinical and environmental conditions while maintaining diagnostic precision and repeatability. SNSI also oversees the calibration, quality control, and performance standardization of these devices, ensuring accuracy, regulatory compliance, and usability in diverse healthcare settings. By enabling rapid, non-invasive chemical sensing and supporting the fusion of volatilomics data with multi-omics insights, SNSI contributes to the identification of early biomarkers of schizophrenia, improves diagnostic timelines, and enhances personalized intervention strategies. Its work ensures that VOLABIOS technologies are not only scientifically rigorous but also clinically viable—helping transition innovative sensing solutions from the lab bench to real-world psychiatric care.